As of October 2023, the Neurosteroid Intervention for Menopausal and Perimenopausal Depression is no longer recruiting participants. Over the last few years we have heard a great deal about neurosteroids, also known as neuroactive steroids. [...]
Menopause is a period of increased risk for women with schizophrenia spectrum disorders, and women are at higher risk for relapse than their age-matched male counterparts.
While many peri- and post-menopausal women request bioidentical hormones, there is no data to suggest that bioidential hormones are safer or more effective than FDA-approved hormone replacement therapies.
It's World Menopause Day. October 18th was designated by the International Menopause Society (IMS) to raise awareness of the menopause and to support options to improve health and well-being for [...]
The FDA accepted a New Drug Application for fezolinetant, a novel, nonhormonal selective neurokinin-3 receptor (NK3R) antagonist for the treatment of menopause-related vasomotor symptoms.
The transition to menopause, or perimenopause, represents the passage from reproductive to non-reproductive life. During the perimenopause, women experience irregular menstrual cycles, which reflect the large fluctuations in ovarian hormone [...]
Although most women transition to menopause without experiencing psychiatric problems, an estimated 20% experience depression at some point during the menopausal transition.
In this episode of It’s Not a Crisis, Dr. Lee Cohen speaks with host Doryn Wallach about the struggles many women experience during the menopausal transition. For most women, menopausal symptoms are manageable, but for [...]
Women with schizophrenia may experience worsening of their symptoms as they transition into the menopause.
While for some adults, attention-deficit/hyperactivity disorder (ADHD) is relatively mild and, with effective treatment, does not have a significant impact on overall functioning or quality of life. However, it is noteworthy that the majority of [...]
